Pharmacogenetics – five decades of therapeutic lessons from genetic diversity

Physicians have long been aware of the subtle differences in the responses of patients to medication. The recognition that a part of this variation is inherited, and therefore predictable, created the field of pharmacogenetics fifty years ago. Knowing the gene variants that cause differences among patients has the potential to allow 'personalized' drug therapy and to avoid therapeutic failure and serious side effects.

[1]  L. H. Snyder.  Studies in Human Inheritance. IX, The Inheritance of Taste Deficiency in Man , 1932 .

[2]  M. Ingelman-Sundberg,et al.  Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[3]  M. Eichelbaum,et al.  Defective N-oxidation of sparteine in man: A new pharmacogenetic defect , 1979, European Journal of Clinical Pharmacology.

[4]  E. Masood.  ⃛ as consortium plans free SNP map of human genome , 1999, Nature.

[5]  Amalia M. Issa,et al.  Ethical perspectives on pharmacogenomic profiling in the drug development process , 2002, Nature Reviews Drug Discovery.

[6]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[7]  L. H. Schmidt,et al.  Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. , 1954, American review of tuberculosis.

[8]  D. Roden,et al.  The genetic basis of variability in drug responses , 2002, Nature Reviews Drug Discovery.

[9]  Mark A. Rothstein,et al.  Ethical and legal implications of pharmacogenomics , 2001, Nature Reviews Genetics.

[10]  David B. Goldstein,et al.  Pharmacogenetics goes genomic , 2003, Nature Reviews Genetics.

[11]  U. Meyer,et al.  Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification , 1990, The Lancet.

[12]  Brewer Gj.  Annotation: human ecology, an expanding role for the human geneticist. , 1971 .

[13]  D. Nebert,et al.  Pharmacogenomics and "individualized drug therapy": high expectations and disappointing achievements. , 2003, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

[14]  Howard L McLeod,et al.  Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.

[15]  E. Vesell,et al.  Twin studies in pharmacogenetics. , 1978, Human genetics. Supplement.

[16]  A E Garrod,et al.  The incidence of alkaptonuria: a study in chemical individuality. 1902. , 1996, Molecular medicine.

[17]  G. Brewer.  Annotation: human ecology, an expanding role for the human geneticist. , 1971, American journal of human genetics.

[18]  N. Davidson,et al.  Pharmacogenetics in the treatment of breast cancer , 2004, The Pharmacogenomics Journal.

[19]  F. Vogel.  Moderne Probleme der Humangenetik , 1959 .

[20]  R. Preisig,et al.  Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man , 2004, European Journal of Clinical Pharmacology.

[21]  A. Garrod.  The Incidence of Alkaptonuria: A study in Chemical Individuality , 1996, Nutrition reviews.

[22]  R. Tyndale,et al.  Decreasing smoking behaviour and risk through CYP2A6 inhibition. , 2003, Drug discovery today.

[23]  W. Kalow,et al.  On distribution and inheritance of atypical forms of human serum cholinesterase, as indicated by dibucaine numbers. , 1957, Canadian journal of biochemistry and physiology.

[24]  A. E. Garrod.  Inborn Errors of Metabolism , 1971 .

[25]  U. Meyer,et al.  Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. , 1990, The Journal of biological chemistry.

[26]  L J Lesko,et al.  Pharmacogenomic-guided drug development: regulatory perspective , 2002, The Pharmacogenomics Journal.

[27]  Andrew Smart,et al.  Tailored medicine: whom will it fit? The ethics of patient and disease stratification. , 2004, Bioethics.

[28]  G R Wilkinson,et al.  Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. , 1994, Molecular pharmacology.

[29]  J. Kahn,et al.  Pharmacogenetic challenges for the health care system. , 2002, Health affairs.

[30]  U. Meyer,et al.  Molecular mechanisms of genetic polymorphisms of drug metabolism. , 1997, Annual review of pharmacology and toxicology.

[31]  J Kirchheiner,et al.  Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders. , 2003, Pharmacopsychiatry.

[32]  B. Alexanderson,et al.  Steady-state plasma levels of nortriptyline in twins: Influence of genetic factors and drug therapy , 1969, British medical journal.

[33]  H. Lehmann,et al.  The familial incidence of low pseudocholinesterase level. , 1956, Lancet.

[34]  P. Danzon,et al.  The economics of gene therapy and of pharmacogenetics. , 2002, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[35]  D. Collier,et al.  Pharmacogenetic prediction of clozapine response , 2000, The Lancet.

[36]  D. Nebert,et al.  Characterization of the common genetic defect in humans deficient in debrisoquine metabolism , 1988, Nature.

[37]  A. Garrod.  The Inborn Factors In Disease , 1931 .

[38]  U. Meyer.  Pharmacogenetics and adverse drug reactions , 2000, The Lancet.

[39]  M Pirmohamed,et al.  Genetic susceptibility to adverse drug reactions. , 2001, Trends in pharmacological sciences.

[40]  G. Shenfield,et al.  The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. , 1996, Pharmacogenetics.

[41]  C. Clayman,et al.  Toxicity of primaquine in Caucasians. , 1952, Journal of the American Medical Association.

[42]  J. S. Miles,et al.  Identification of the primary gene defect at the cytochrome P450 CYP2D locus , 1990, Nature.

[43]  R. Weinshilboum.  Inheritance and drug response. , 2003, The New England journal of medicine.

[44]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[45]  Y Miura,et al.  [Biochemical individuality]. , 1973, [Kango gijutsu] : [Nursing technique].

[46]  E. D. Cyan.  Pharmacogenetics: Heredity and the Response to Drugs. , 1963 .

[47]  L. Bertilsson,et al.  Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. , 1985, Therapeutic drug monitoring.

[48]  Klaus Lindpaintner,et al.  Pharmacogenetics and the future of medical practice. , 2002, Journal of molecular medicine.

[49]  A. Roses.  Pharmacogenetics and the practice of medicine , 2000, Nature.

[50]  W. M. Wheeler,et al.  Mendel's principles of heredity; a defence by W. Bateson ... With a translation of Mendel's original papers on hybridisation. , 2022 .

[51]  C. Handschin,et al.  Induction of drug metabolism: the role of nuclear receptors. , 2008, Pharmacological reviews.

[52]  A. L. Fox.  The Relationship between Chemical Constitution and Taste. , 1932, Proceedings of the National Academy of Sciences of the United States of America.

[53]  R. Bönicke,et al.  Enzymatische Inaktivierung von Isonicotinsäurehydrazid im menschlichen und tierischen Organismus , 2004, Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie.

[54]  M. Brodie,et al.  Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver. , 1982, British journal of clinical pharmacology.

[55]  R. Skoda,et al.  Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[56]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[57]  W. Weber,et al.  Diverse point mutations in the human gene for polymorphic N-acetyltransferase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[58]  F. Guengerich,et al.  Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. , 1985, The Journal of biological chemistry.

[59]  Donna R. Savage.  FDA guidance on pharmacogenomics data submission , 2003, Nature Reviews Drug Discovery.

[60]  R. Kerwin,et al.  Genetic Predictors of Therapeutic Response to Clozapine , 2002, CNS drugs.

[61]  D. Grant,et al.  Molecular mechanism of slow acetylation of drugs and carcinogens in humans. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[62]  H. Hauri,et al.  Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[63]  Ulrich M. Zanger,et al.  Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.

[64]  P. Carson,et al.  Enzymatic deficiency in primaquine-sensitive erythrocytes. , 1956, Science.

[65]  M. Cronin,et al.  Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. , 2000, Journal of clinical psychopharmacology.

[66]  V. McKusick,et al.  Genetic Control of Isoniazid Metabolism in Man , 1960, British medical journal.

[67]  H. Hughes.  On the metabolic fate of isoniazid. , 1953, The Journal of pharmacology and experimental therapeutics.

[68]  D. Goldstein.  Pharmacogenetics in the laboratory and the clinic. , 2003, New England Journal of Medicine.

[69]  M. Relling,et al.  Nomenclature for N-acetyltransferases. , 1995, Pharmacogenetics.

[70]  P. Evans,et al.  Genetic Factors in Drug Therapy: Clinical and Molecular Pharmacogenetics , 1994 .

[71]  Human genetic variations in oxidative drug metabolism. , 1986, Xenobiotica; the fate of foreign compounds in biological systems.

[72]  C. Clayman,et al.  3. TOXICITY OF PRIMAQUINE IN CAUCASIANS , 1952 .

[73]  A. Motulsky.  Drug reactions enzymes, and biochemical genetics. , 1957, Journal of the American Medical Association.

[74]  J. Nabarro,et al.  Clinical experience with chlorothiazide. , 1958, Lancet.

[75]  T. Kronbach,et al.  Debrisoquine‐type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation , 1984, FEBS letters.

[76]  M. Ingelman-Sundberg,et al.  Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine , 1993, The Lancet.

[77]  M. Eastwood,et al.  NEUTROPHIL FUNCTION AND MYELOPEROXIDASE ACTIVITY IN INFLAMMATORY BOWEL DISEASE , 1976, The Lancet.